Podcast Summary: The Megyn Kelly Show – Ep. 1051

Title: Fighting the Swamp and Conflicts of Interest, Truth About DOGE Cuts, and Finding Autism Cause, with FDA Commissioner Dr. Marty Makary
Host: Megyn Kelly
Guest: Dr. Marty Makary, FDA Commissioner
Release Date: April 17, 2025

1. Introduction to Dr. Marty Makary and His Appointment at the FDA

Megyn Kelly opens the episode by introducing Dr. Marty Makary, highlighting his impressive credentials and the challenges he faces as the new FDA Commissioner. Dr. Makary is portrayed as a dedicated surgeon and scientist with a strong commitment to public health, known for his honest stance on controversial issues like COVID-19.

Megyn Kelly [00:00]: "He's a surgeon, scientist, has devoted his life to public health... he became one of the trusted voices... Dr. Makary is the real deal."

2. Shifting Focus from Drug Approvals to Chronic Disease Prevention

Dr. Makary emphasizes the FDA's need to pivot from solely focusing on drug approvals to addressing the rising tide of chronic diseases in the population. He points out alarming statistics about autoimmune diseases, pre-diabetes in teens, and declining health standards.

Dr. Marty Makary [04:34]: "We do great with sophisticated operations and amazing drugs... but when it comes to the health of the population right now, we have had this massive area that we're not talking about... the rise of all these chronic diseases."

3. Reforming FDA Culture: From Siloed Operations to Teamwork

Upon taking office, Dr. Makary discovered that the FDA was operating in silos, with each center functioning independently. His immediate goal is to foster a culture of teamwork and integrated operations to enhance efficiency and effectiveness.

Dr. Marty Makary [05:52]: "We're trying to change the culture here to make it more of a teamwork culture. It's been very siloed."

4. Addressing the Divide in Medical Approaches: Traditional vs. Functional Medicine

The discussion delves into the existing divide between traditional medical practices and the emerging functional medicine approach. Dr. Makary advocates for a balanced integration of both to tackle chronic diseases more effectively.

Dr. Marty Makary [06:18]: "We need both. We need people who think broadly and think functionally... we need the old guard to ensure that we hold to rigorous scientific methodology, and we need fresh new ideas at the same time."

5. Restoring Trust in the FDA: Lessons from Past Corruptions

Dr. Makary addresses historical issues of corruption within the FDA, citing the OxyContin approval and subsequent industry relationships as prime examples of regulatory capture. He underscores the importance of independent scientific evaluation to rebuild public trust.

Dr. Marty Makary [08:48]: "The person who literally authorized OxyContin then went to work for Purdue Pharma... that kind of mistake can result in a million Americans losing their lives."

6. Overhauling Advisory Committees to Eliminate Conflicts of Interest

A significant reform discussed is the removal of industry members from FDA advisory committees. Dr. Makary announces that future committees will prioritize patients and family caregivers over pharmaceutical representatives to ensure unbiased decision-making.

Dr. Marty Makary [21:13]: "We are removing industry members, pharma members from FDA advisory committees. We're replacing them... with patients and family givers."

7. Reducing and Replacing Animal Testing with Modern Technologies

Highlighting ethical concerns, Dr. Makary reveals the FDA's initiative to minimize animal testing. He introduces alternative methods like computational modeling and organ-on-a-chip technology to predict drug toxicity, aiming to expedite the approval process while ensuring safety.

Dr. Marty Makary [30:42]: "We are taking steps to reduce animal testing requirements and to stop unnecessary animal testing... organ on a chip technology can replace this."

8. Revamping Nutrition Guidelines and Enhancing School Lunch Programs

A cornerstone of Dr. Makary's agenda is the complete overhaul of the traditional food pyramid. The FDA plans to focus on food ingredients and their impact on the microbiome, aiming to combat chronic diseases. Additionally, the FDA is launching grant programs to help schools transition to healthier lunch options.

Dr. Marty Makary [38:19]: "We're redoing the food pyramid... We're going to help schools get off the cupcakes... provide guidance on healthier foods."

9. Investigating the Rise of Autism: The Role of the Microbiome

Dr. Makary discusses the dramatic increase in autism diagnoses, proposing that disruptions to the microbiome may play a significant role. He advocates for comprehensive research into environmental and dietary factors that could influence microbiome health and, consequently, the prevalence of autism.

Dr. Marty Makary [41:35]: "We have to look at everything... the cumulative burden of all of these exposures, environmental and dietary, that alter the microbiome."

10. Enhancing FDA Operations with Artificial Intelligence

To streamline the drug approval process, the FDA is integrating AI technologies. These advancements aim to reduce the time required for drug approvals and lower research and development costs, ultimately benefiting both pharma companies and the public.

Dr. Marty Makary [32:30]: "We're introducing AI into the review process to help the reviewer, to make the reviewer's workstream much more streamlined and summarize things."

11. Combating Public Distrust and Misconceptions

Dr. Makary acknowledges the deep-seated distrust in the FDA, partly due to previous administrations' mishandling of data and oversight. He commits to transparency and rigorous scientific methods to dispel misinformation and restore confidence in the agency.

Dr. Marty Makary [14:15]: "We're going to know. We're going to do intense comprehensive research."

12. Future Directions and Closing Remarks

In his closing statements, Dr. Makary reiterates his commitment to independent scientific evaluation, healthier food initiatives, and restoring public trust in the FDA. He expresses optimism about the positive changes underway and his dedication to serving the American people without future industry ties.

Dr. Marty Makary [58:36]: "We are not gonna be shutting down ideas... together we can do both. Healthier food for children, rebuilding the public trust and focusing... on cures and meaningful treatments for Americans."

Notable Quotes with Timestamps

• Megyn Kelly [00:00]: "He's a surgeon, scientist, has devoted his life to public health... he became one of the trusted voices... Dr. Makary is the real deal."

• Dr. Marty Makary [04:34]: "We do great with sophisticated operations and amazing drugs... but when it comes to the health of the population right now, we have had this massive area that we're not talking about... the rise of all these chronic diseases."

• Dr. Marty Makary [06:18]: "We need both. We need people who think broadly and think functionally... we need the old guard to ensure that we hold to rigorous scientific methodology, and we need fresh new ideas at the same time."

• Dr. Marty Makary [21:13]: "We are removing industry members, pharma members from FDA advisory committees. We're replacing them... with patients and family givers."

• Dr. Marty Makary [32:30]: "We're introducing AI into the review process to help the reviewer, to make the reviewer's workstream much more streamlined and summarize things."

• Dr. Marty Makary [38:21]: "We're redoing the food pyramid... We're going to help schools get off the cupcakes... provide guidance on healthier foods."

• Dr. Marty Makary [41:35]: "We have to look at everything... the cumulative burden of all of these exposures, environmental and dietary, that alter the microbiome."

• Dr. Marty Makary [58:36]: "We are not gonna be shutting down ideas... together we can do both. Healthier food for children, rebuilding the public trust and focusing... on cures and meaningful treatments for Americans."

Conclusion

In this episode, Dr. Marty Makary outlines a comprehensive plan to transform the FDA by addressing systemic corruption, embracing innovative technologies, and refocusing on preventive health measures. His approach emphasizes transparency, ethical governance, and a balanced integration of traditional and functional medical practices to enhance public health and regain public trust.